Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Viatris Inc (VTRS) Price & Performance

Duolingo IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Viatris Inc — how do they compare? Duolingo Inc trades at $149.92 (market cap $7.08B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.8× Duolingo Inc's market cap, and Viatris Inc pays a 2.75% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Viatris Inc for 57 Days on average.

DUOLVTRS
Market Cap
$7.08B$20.03B
Volume
729,17114,109,977
Sector
TechnologyHealth
52-Week High
$341.08$18.27
52-Week Low
$90.03$9.74
Typical Hold Time
137 Days57 Days
Enterprise Value
$5.85B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $151.22, down 0.33% on the day, as the stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong growth with revenue reaching $1.04 billion in 2025 and net income of $414 million, representing a robust 35.87% net margin. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Analyst sentiment remains divided with a 37.5% buy rating consensus amid ongoing insider selling activity.

The outlook remains cautiously optimistic as Duolingo's AI-driven growth strategy and expanding user base support continued revenue expansion, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share liquidations, competitive pressures in edtech, and the challenge of sustaining high profit margins. The stock trades near analyst consensus targets, suggesting limited near-term upside potential from current levels.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DUOL
18% Buy82% Sell
Avg holding period · 137 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →